SCHEMBL17521900

SCHEMBL17521900

NCCOCCOC1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1OC(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF2R P11717 4/20 0.56
CXCL10 P02778 1/20 0.47
CXCL8 P10145 1/20 0.47
CCL2 P13500 1/20 0.47
CCL5 P13501 1/20 0.47
CXCL12 P48061 1/20 0.47
CD209 Q9NNX6 2/20 0.41
LGALS3 P17931 3/20 0.40
LGALS8 O00214 2/20 0.40
LGALS4 P56470 2/20 0.40
IFNG P01579 1/20 0.35
FGF1 P05230 1/20 0.35
FGF2 P09038 1/20 0.35
BMP2 P12643 1/20 0.35
VEGFA P15692 1/20 0.35
SFRP1 Q8N474 1/20 0.35
GJA1 P17302 1/20 0.34
GJB2 P29033 1/20 0.34
MEN1 O00255 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17521920 0.93 IGF2R (0.60) IGF2RCXCL10CXCL8CCL2CCL5
SCHEMBL17521939 0.93 IGF2R (0.57) IGF2RCXCL10CXCL8CCL2CCL5
SCHEMBL17521929 0.93 IGF2R (0.57) IGF2RCXCL10CXCL8CCL2CCL5
SCHEMBL16126199 0.93 IGF2R (0.57) IGF2RCXCL10CXCL8CCL2CCL5
SCHEMBL17521901 0.87 IGF2R (0.53) IGF2RCXCL10CXCL8CCL2CCL5
SCHEMBL21083270 0.87 IGF2R (0.65) IGF2RCXCL10CXCL8CCL2CCL5
SCHEMBL21083292 0.87 IGF2R (0.65) IGF2RCXCL10CXCL8CCL2CCL5
SCHEMBL16126762 0.85 IGF2R (0.44) IGF2RCXCL10CXCL8CCL2CCL5
SCHEMBL17521951 0.85 IGF2R (0.44) IGF2RCXCL10CXCL8CCL2CCL5
SCHEMBL16126954 0.85 IGF2R (0.67) IGF2RCXCL10CXCL8CCL2CCL5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9919055-B2 Sugar-linker-drug conjugates ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-20 US disclosed
US-20160045611-A1 SUGAR-LINKER-DRUG CONJUGATES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-02-18 US disclosed
US-20160045611-A1 SUGAR-LINKER-DRUG CONJUGATES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160045611-A1 SUGAR-LINKER-DRUG CONJUGATES FUT5, FUT6, B3GNT2 IGF2R 1906/4885CXCL10 3377/4885CXCL8 3983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.